Announcement of R&D expenses of 71 pharmaceutical companies: Yiling, Baiyunshan, China Resources Sanjiu...

01 Announcement of R&D expenses of pharmaceutical companies

Recently, the WeChat public account "Pharmaceuticals", according to the biological classification of Shenwan Hongyuan Pharmaceuticals, counted the R&D expenditures of 71 pharmaceutical companies in the A-share Chinese medicine sector in the first three quarters of 2021

There are 12 pharmaceutical companies with R&D expenses exceeding 100 million yuan in the first three quarters of 2021, namely Baiyunshan (605 million yuan), Yiling (538 million yuan), Tasly (397 million yuan), and China Resources Sanjiu (355 million yuan) ), Kangyuan Pharmaceutical (337 million yuan), Buchang (261 million yuan), Jichuan Pharmaceutical (220 million yuan), Yunnan Baiyao (196 million yuan), Guilin Sanjin (170 million yuan), Kangenbei (136 million yuan), Hongri Pharmaceutical (116 million yuan), and Yabao Pharmaceutical (114 million yuan)

Image source: WeChat public account "Pharmaceutical Aspects"

In recent years, in order to encourage innovation in traditional Chinese medicine, the State Food and Drug Administration has issued a series of documents to promote the registration and application of new traditional Chinese medicines

According to the data from Minet.

As the pace of centralized procurement of Chinese patent medicines continues to accelerate, more and more companies choose to invest more in research and development, and attach importance to the innovative research and development of Chinese patent medicines with real clinical value

Judging from the year-on-year growth of R&D expenses, 19 pharmaceutical companies have exceeded 40%, namely Tibet Pharmaceutical, Rhine Bio, Zhongheng Group, Xintian Pharmaceutical, Guizhou Bailing, Datang Pharmaceutical, Yabao Pharmaceutical, Huluwa, Renhe Pharmaceutical, Zuoli Pharmaceutical, Guilin Sanjin, Yunnan Baiyao, Tongrentang, Baiyunshan, Zhongsheng Pharmaceutical, Essence Pharmaceutical, Xiangxue Pharmaceutical, Sunflower Pharmaceutical, Jiangzhong Pharmaceutical

Image source: WeChat public account "Pharmaceutical Aspects"

Relevant people in the industry believe that according to the current development trend of new traditional Chinese medicines, the market size is expected to exceed one trillion yuan in 2022, and will reach 1.

02 These pharmaceutical companies are outstanding

Baiyun Mountain

In the first three quarters of 2021, Baiyun Mountain achieved revenue of 53.

Bai Yunshan once stated on the investment interactive platform that according to the company's 2020 annual report, as of December 31, 2020, the number of its R&D personnel was 556, and it will continue to promote and increase scientific research innovation and product research and development efforts, and strengthen the construction of scientific research platforms

At present, a total of 325 varieties of Baiyunshan and its joint ventures are included in the National Medical Insurance Catalogue, 331 varieties are included in the Provincial Medical Insurance Catalogue, and 143 varieties are included in the Essential Medicines List; the main traditional Chinese medicine products include Xiaoke Pills, Compound Danshen Tablets Series, Banlangen Granules Series, Qingkailing Series, Zishen Yutai Pills, Xiao Chaihu Granules, Huatuo Zaizao Pills, Xia Sangju Granules, Children Qixing Tea Granules, Zhuangyao Jianshen Pills, Angong Niuhuang Pills,

Baiyunshan's patented Chinese patent medicine products are Xiaoke Pills, Zishen Yutai Pills, Xiaochaihu Granules and Qingkailing series

From the perspective of product revenue, the main product of Baiyunshan Chinese patent medicine in 2020 is Xiaoke Pills, with revenue reaching 455 million yuan

It is worth noting that the patent date of Zishen Yutai Pill is August 27, 2024, while the patent period of Xiaoke Pill is March 31, 2026

Yiling

In the first half of 2021, Yiling achieved revenue of 5.

In the post-epidemic era, Yiling Pharmaceutical's Lianhua Qingwen, as the core product recognized by the state to effectively prevent and treat the new coronavirus, achieved revenue of 2.

In recent years, Yiling Pharmaceutical has continued to increase its R&D investment to improve its innovation capability.

At present, in terms of traditional Chinese medicine, Yiling combines the theoretical research on collateral diseases with the research and development of clinical major diseases and innovative traditional Chinese medicines, and has developed and marketed 12 patented traditional Chinese medicines with independent intellectual property rights, of which 8 are listed in the National Medical Insurance Catalogue and 5 are national bases.
drug species
.

China Resources Sanjiu

According to the 2021 third quarter performance report of China Resources Sanjiu, the revenue in the first three quarters was about 11.
099 billion yuan, a year-on-year increase of 19.
17%; the net profit was about 1.
741 billion yuan, a year-on-year increase of 10.
13%
.

According to the 2021 semi-annual report of China Resources Sanjiu, its newly established products mainly focus on the fields of gynecology and pediatrics
.

China Resources Sanjiu stated in an investor relations record form that it follows the development characteristics of traditional Chinese medicine and has formulated a long-term research and development plan for traditional Chinese medicine around "innovative traditional Chinese medicine + development of classic prescriptions + development of in-hospital preparations"
.

In terms of innovative traditional Chinese medicine, focus on the varieties of traditional Chinese medicine with unique curative effect, and cultivate large varieties of traditional Chinese medicine; in the development of classic prescriptions, more than ten classic prescriptions are currently under research, and some of the researched varieties have completed the application materials
.

As the inter-provincial alliances have successively released news about Chinese medicine companies winning bids in bulk purchases, the market's expectations for the performance of pharmaceutical companies have been increasing
.
Huaan Securities analyzed in a research report that the competition in the traditional Chinese medicine market is relatively large, and the brand competitiveness of enterprises will decline with the addition of substitutes, thus facing the risk of declining profit margins
.

In this context, relevant pharmaceutical companies must continuously improve their research and development capabilities in order to enhance their market competitiveness
.